Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082803 · ClinicalTrials.gov registry record · Phase 1
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
A Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Treeline Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 11
- Study locations
NCT07082803: Recruiting Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Treeline Biosciences.
NCT07082803 is a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin that is actively recruiting participants, run by Treeline Biosciences. The registered enrollment target is 180 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (63% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07082803, a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, is actively recruiting participants, sponsored by Treeline Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 11
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Conditions Studied
Interventions
- DRUG TLN-121
- DRUG TLN-254
Study Locations (11)
Victoria
- Cabrini Health - Malvern
- Peter MacCallum Cancer Centre - Melbourne
California
- Stanford Medicine Cancer Center - Palo Alto
Michigan
- The START Center for Cancer Care - Midwest - Grand Rapids
Missouri
- Washington University School of Medicine - St Louis
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- The University of Texas MD Anderson Cancer Center - Houston
New South Wales
- Macquarie University Hospital - Macquarie Park
Queensland
- Princess Alexandra Hospital - Woolloongabba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2030-11 |
| Phase | Phase 1 |
What NCT07082803 shows while recruiting
NCT07082803 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which TLN-121 is the first listed.
NCT07082803 lists 11 locations in 10 states (Victoria, California, Michigan).
Frequently Asked Questions
What is clinical trial NCT07082803 about?
NCT07082803 is a clinical study titled "TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas". The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
What is the current status of trial NCT07082803?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2025-06-23. Estimated completion is 2030-11.
What conditions does trial NCT07082803 study?
This clinical trial studies the following conditions: Lymphoma, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT07082803?
The interventions under investigation include: TLN-121 (DRUG), TLN-254 (DRUG).
Who is sponsoring clinical trial NCT07082803?
This trial is sponsored by Treeline Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082803 being conducted?
This trial has 11 study locations across California, Michigan, Missouri, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07082803's enrollment target sits among peer trials
180 52nd of 299 higher than 247 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI